PRPO:NASDAQPrecipio, Inc. Analysis
Data as of 2026-06-18 - not real-time
$22.36
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Precipio trades near its 20‑day SMA, which sits just below the 200‑day SMA, suggesting a neutral price bias. The 14‑day RSI is in the lower third of its range, hinting at modest downside pressure but also room for a rebound. A bullish MACD histogram, albeit small, indicates a potential short‑term upside momentum. Volatility is elevated at over 45% on a 30‑day basis, while beta remains low, reflecting high price swings that are not strongly correlated with the broader market. The stock’s forward PE of roughly 57× dwarfs the industry average of 24×, and the discounted cash‑flow model values the company at just over $1, far below the current market price of $22, flagging a significant overvaluation. Meanwhile, the company reports negative operating and profit margins, modest cash generation, and a decreasing volume trend, all of which temper optimism.
Fundamentally, the firm’s revenue growth is strong but not enough to offset ongoing losses and a high debt‑to‑equity ratio. The lack of dividend and a weak free cash flow profile further limit income‑oriented appeal. Technical support sits near $21.4, with resistance around $25.6, framing a relatively narrow trading range. Given the combination of high valuation, negative earnings, and elevated volatility, the outlook leans toward caution, with a bias toward holding rather than adding new positions.
Fundamentally, the firm’s revenue growth is strong but not enough to offset ongoing losses and a high debt‑to‑equity ratio. The lack of dividend and a weak free cash flow profile further limit income‑oriented appeal. Technical support sits near $21.4, with resistance around $25.6, framing a relatively narrow trading range. Given the combination of high valuation, negative earnings, and elevated volatility, the outlook leans toward caution, with a bias toward holding rather than adding new positions.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near technical support level
- Bullish MACD histogram
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 4/10
Key Factors
- Significant overvaluation relative to DCF
- Negative operating margins and cash flow
- Decreasing volume trend
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Sustained earnings losses and high PE
- Weak balance‑sheet metrics
- DCF valuation far below market price
Key Metrics & Analysis
Financial Health
Revenue Growth36.20%
Profit Margin-3.57%
P/E Ratio57.3
ROE-7.13%
ROA-5.74%
Debt/Equity24.65
P/B Ratio2.8
Op. Cash Flow$793.0K
Free Cash Flow$84.8K
Industry P/E24.3
Technical Analysis
TrendNeutral
RSI37.4
Support$21.37
Resistance$25.60
MA 20$23.12
MA 50$26.46
MA 200$23.58
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value$1.23
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.26
Volatility47.36%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.